{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T16:06:20Z","timestamp":1774886780536,"version":"3.50.1"},"reference-count":26,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OTT"],"DOI":"10.2147\/ott.s219449","type":"journal-article","created":{"date-parts":[[2020,6,7]],"date-time":"2020-06-07T22:44:05Z","timestamp":1591569845000},"page":"5123-5133","source":"Crossref","is-referenced-by-count":13,"title":["&lt;p&gt;Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed\/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data&lt;\/p&gt;"],"prefix":"10.2147","volume":"Volume 13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6355-3671","authenticated-orcid":true,"given":"Yazeed","family":"Sawalha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8519-8404","authenticated-orcid":true,"given":"Kami","family":"Maddocks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1182\/blood-2009-02-205500","volume":"114","author":"Dornan","year":"2009","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.molimm.2004.04.008","volume":"41","author":"Dal Porto","year":"2004","journal-title":"Mol Immunol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/00129039-200106000-00001","volume":"9","author":"Chu","year":"2001","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1182\/blood-2007-01-066704","volume":"110","author":"Polson","year":"2007","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e54938","DOI":"10.1371\/journal.pone.0054938","volume":"8","author":"Busman-Sahay","year":"2013","journal-title":"PLoS One"},{"key":"ref6","first-page":"413","volume":"84","author":"Cabezudo","year":"1999","journal-title":"Haematologica"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/1096-8652(200008)64:4<275::aid-ajh7>3.0.co;2-y","volume":"64","author":"D\u2019Arena","year":"2000","journal-title":"Am J Hematol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1038\/leu.2015.48","volume":"29","author":"Pfeifer","year":"2015","journal-title":"Leukemia"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/bph.13697","volume":"174","author":"Fuh","year":"2017","journal-title":"Br J Pharmacol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"4279","DOI":"10.1182\/blood-2019-128305","volume":"134","author":"Allan","year":"2019","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/S1470-2045(15)70128-2","volume":"16","author":"Palanca-Wessels","year":"2015","journal-title":"Lancet Oncol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S2352-3026(19)30026-2","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"JCO1900172","DOI":"10.1200\/JCO.19.00172","volume":"38","author":"Sehn","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"7507","DOI":"10.1200\/JCO.2018.36.15_suppl.7507","volume":"36","author":"Sehn","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1200\/JCO.19.00010","volume":"37","author":"Leonard","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1056\/NEJMoa1805104","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e429","DOI":"10.1016\/S2352-3026(19)30089-4","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1182\/blood-2019-131045","volume":"134","author":"Fowler","year":"2019","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1182\/blood-2019-129422","volume":"134","author":"Nastoupil","year":"2019","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1182\/blood-2019-123669","volume":"134","author":"Diefenbach","year":"2019","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S1470-2045(19)30091-9","volume":"20","author":"Tilly","year":"2019","journal-title":"Lancet Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","volume":"35","author":"Vitolo","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref24","unstructured":"Genentech Inc. PolivyTM (Polatuzumab vedotin-piiq) for injection, for intravenous use: US Prescribing Information; 2019. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761121s000lbl.pdf. Accessed February 21, 2020."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"3963","DOI":"10.1182\/blood-2019-128580","volume":"134","author":"Audino","year":"2019","journal-title":"Blood"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"4140","DOI":"10.1182\/blood.V130.Suppl_1.649.649","volume":"130","author":"Herrera","year":"2017","journal-title":"Blood"}],"container-title":["OncoTargets and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=58669","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=58669","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T23:38:46Z","timestamp":1666827526000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/profile-of-polatuzumab-vedotin-in-the-treatment-of-patients-with-relap-peer-reviewed-article-OTT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":26,"URL":"https:\/\/doi.org\/10.2147\/ott.s219449","relation":{},"ISSN":["1178-6930"],"issn-type":[{"value":"1178-6930","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6]]}}}